Search results
PROMOTED
How do worsening heart events dictate the long-term outcomes of patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and can earlier intervention influence the disease trajectory in ATTR-CM? In this new sub-analysis from ATTRibute-CM, recorded onsite at ESC Heart Failure Congress (HFA) 2026, Prof Marianna Fontana (University College London, London, UK) sheds further light onto these…
View more
HFA 2026: Updates on ATTR-CM
Added:
2 days ago
Video Series
Added:
3 months ago
In this episode of Arrhythmia Academy's Journal Club, Dr David Duncker (Hannover Heart Rhythm Center, DE) is joined by Dr Marat Fudim (Duke University, US) to examine the critical early-risk period following heart failure diagnosis and the emerging role of wearable cardioverter defibrillators in sudden cardiac death prevention.The discussion centres on findings from the SCD-PROTECT study, a 19…
View more
Added:
3 days ago
In this episode of Masterclass, host, Dr Harriette Van Spall speaks with Professor Faiez Zannad about the challenge of making heart failure evidence more globally representative.Professor Zannad is an emeritus Professor of Therapeutics and Cardiology at the University of Lorraine in Nancy, France, and a leading clinical trialist in heart failure whose studies have informed international treatment…
View more
Staging of Heart Failure with Preserved Ejection Fraction
Added:
1 year ago
Expert Opinion
Added:
6 months ago
AHA Scientific Sessions 2025 - Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview…
View more
Added:
1 month ago
ACC.26 - In this expert interview filmed at ACC.26 in New Orleans, Prof. Felipe Martínez discusses how late-breaking heart failure data are reshaping contemporary pharmacological management. The conversation focuses on new spironolactone results, advanced hemodynamic strategies in HFpEF, and the expanding role of cardiometabolic therapies, including GLP‑1 receptor agonists, in optimising outcomes…
View more
Added:
8 months ago
Discover the rapidly evolving therapeutic options transforming outcomes for cardiac amyloidosis patients with Dr Sarah Cuddy.This comprehensive presentation, part of the Cardiomyopathies track, explores the dramatic advances in both TTR and AL amyloidosis treatment over the past decade. Dr Cuddy examines how modern therapeutic approaches have fundamentally shifted survival curves, particularly…
View more
Added:
8 months ago
Navigate the diagnostic complexities of cardiac amyloidosis through expert multimodality imaging techniques with Dr Vasvi Singh.This comprehensive presentation, part of the Cardiomyopathies track, addresses the critical role of advanced imaging in diagnosing cardiac amyloidosis. Dr Singh explores the nuanced differences between SPECT and SPECT-CT imaging capabilities, providing practical insights…
View more
Cardiac Troponins in Kidney Disease
Added:
9 months ago
Review Article
Targeting Obesity for Heart Failure
Added:
4 months ago
Review Article